Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company pioneering novel therapies for multidrug-resistant bacterial infections and rare diseases. This page serves as the definitive source for verified news and official updates on SPRO's research advancements, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely updates on key programs including tebipenem HBr (oral carbapenem antibiotic), SPR206 (IV polymyxin), and other pipeline developments. The curated news collection covers clinical trial results, FDA communications, partnership announcements, and financial disclosures.
All content is rigorously verified to ensure accuracy and relevance for stakeholders monitoring antibiotic innovation. Bookmark this page for direct access to SPRO's latest developments in addressing critical unmet medical needs through advanced therapeutic candidates.
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focusing on rare diseases and multi-drug resistant bacterial infections, has announced its participation in two upcoming investor conferences in September 2024:
1. H.C. Wainwright 26th Annual Global Investment Conference in New York, NY (September 9-11, 2024)
- Presentation: September 10, 2024, 4:00 - 4:30 PM ET
2. Cantor's Global Healthcare Conference in New York, NY (September 17-19, 2024)
- Fireside Chat: September 17, 2024, 1:20 - 1:50 PM ET
Sath Shukla, President and CEO of Spero Therapeutics, will present at both events and be available for one-on-one meetings. Webcasts of both presentations will be accessible through Spero's website, with replays available after the events.
Spero Therapeutics (NASDAQ: SPRO) announced Q2 2024 results and provided a business update. Key highlights include:
- Enrollment concluded in Phase 2a trial of SPR720 for NTM-PD; preliminary data expected in Q4 2024
- New SPR720 in-vitro resistance data to be presented at IDWeek 2024
- CMO Kamal Hamed departing; John C. Pottage, Jr., M.D. appointed as Special Advisor
- Cash balance of $63.5 million as of June 30, 2024; runway into late 2025
- Q2 2024 net loss of $17.9 million, or ($0.33) per share
- Total revenue increased to $10.2 million in Q2 2024 from $2.7 million in Q2 2023
- R&D expenses increased to $23.7 million in Q2 2024 from $9.5 million in Q2 2023
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focusing on rare diseases and multi-drug resistant (MDR) bacterial infections, has announced its upcoming second quarter 2024 financial results and business update. The company will host a conference call and live audio webcast on Monday, August 5th, 2024, at 4:30 p.m. ET.
Investors and interested parties can access the call by dialing 1-877-269-7751 (domestic) or 1-201-389-0908 (international) and referring to conference ID 13747505. Alternatively, they can request a return call or access the live audio webcast through the provided link. The webcast will also be available on Spero's Investor Relations webpage and archived for 30 days following the call.
Spero Therapeutics announced the approval of 227,500 restricted stock unit (RSU) awards to new employees. This grant was made under the company's 2019 Inducement Equity Incentive Plan and approved by the Compensation Committee of Spero's Board of Directors on May 28, 2024. The RSUs are provided as an inducement for new employees to join Spero, in line with Nasdaq Listing Rule 5635(c)(4). These RSUs will vest in four equal annual installments starting on July 1, 2025, contingent upon the employees' continued employment with Spero. The grants are governed by the terms of the 2019 Inducement Plan and respective RSU agreements.
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, announced on June 3, 2024, that its Board's Compensation Committee approved the grant of 116,667 restricted stock units (RSUs) under its 2019 Inducement Equity Incentive Plan. The RSUs serve as an inducement for a new employee, in line with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four annual installments starting June 1, 2025, contingent on the employee's continued employment.
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in treatments for rare diseases and multi-drug-resistant bacterial infections, will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will take place on May 20, 2024, at NASDAQ World Headquarters in New York, NY. During the conference, Spero's President and CEO, Sath Shukla, will engage in a fireside chat and one-on-one meetings. The session is scheduled from 1:30 - 2:00 PM ET and will be accessible via webcast on Spero's website, with a replay available post-event.
Spero Therapeutics (Nasdaq: SPRO) reported its Q1 2024 financial results and provided a business update. The company continues advancing its clinical pipeline, with key trials underway. Topline data for SPR720, aimed at treating NTM-PD, is expected in 2H 2024. The Phase 3 trial for tebipenem HBr in cUTI is ongoing, with enrollment completion targeted for 2H 2025. SPR206 received FDA Fast Track designation for HABP/VABP treatment.
Spero reported a net loss of $12.7 million for Q1 2024, a slight improvement from $13.3 million a year ago. Revenue surged to $9.3 million, primarily due to increased collaboration and grant revenues. R&D expenses rose to $17.3 million, reflecting heightened clinical activity. G&A expenses decreased to $5.9 million. The company's cash balance stands at $82.3 million, up from $76.3 million at year-end 2023, bolstered by a $23.8 million milestone payment from GSK. Spero's financial runway is expected to extend into late 2025.
Spero Therapeutics, Inc. (Nasdaq: SPRO) will report its first quarter 2024 financial results and business update on May 15, 2024. The company focuses on developing treatments for rare diseases and MDR bacterial infections.
Spero Therapeutics, Inc. announced the approval of 10,833 restricted stock unit awards to a new employee under the 2019 Inducement Plan. The RSUs will vest in four equal annual installments beginning on May 1, 2025, subject to the employee's continued employment.